(Total Views: 294)
Posted On: 03/15/2020 7:30:46 AM
Post# of 22467
Right, there are thousands of biotechs and it is a high risk, high return industry.
Years ago QMC had a relationship with Nanoaxis which is no longer around.
Pharmas sometimes partner with a biotech or buy them out when they have results.
A better path might be to find those ready soon to go to mass production of their drug and at that point arrange to license QD or perhaps JV a QD reactor for royalties, if its a large enough deal. QD could be a major cost and a JV lowers that at the front end by QMC providing the QD and getting royalties on the backend. Just IMO.
Years ago QMC had a relationship with Nanoaxis which is no longer around.
Pharmas sometimes partner with a biotech or buy them out when they have results.
A better path might be to find those ready soon to go to mass production of their drug and at that point arrange to license QD or perhaps JV a QD reactor for royalties, if its a large enough deal. QD could be a major cost and a JV lowers that at the front end by QMC providing the QD and getting royalties on the backend. Just IMO.
(1)
(0)
